Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder

被引：40
|
作者：
Brandl, E. J. [1 ,2 ]
Tiwari, A. K. [1 ,2 ]
Zhou, X. [2 ,3 ]
Deluce, J. [2 ,3 ]
Kennedy, J. L. [1 ,2 ]
Mueller, D. J. [1 ,2 ]
Richter, M. A. [1 ,2 ,3 ]
机构：
[1] Ctr Addict & Mental Hlth, Dept Neurosci, Neurogenet Sect, Campbell Family Mental Hlth Res Inst, Toronto, ON, Canada
[2] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[3] Sunnybrook Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada
来源：
PHARMACOGENOMICS JOURNAL | 2014年 / 14卷 / 02期
关键词：
obsessive-compulsive disorder (OCD); pharmacogenetics; CYP2D6; CYP2C19; treatment response; EVIDENCE-BASED PHARMACOTHERAPY; SEROTONIN REUPTAKE INHIBITORS; JAPANESE PSYCHIATRIC-PATIENTS; CYTOCHROME-P450; 2D6; GENOTYPE; STAR-ASTERISK-D; PLASMA-CONCENTRATIONS; DEPRESSED-PATIENTS; THERAPEUTIC RESPONSE; CLINICAL-RESPONSE; ACTIVITY SCORE;
D O I：
10.1038/tpj.2013.12
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Numerous studies have reported on pharmacogenetics of antidepressant response in depression. In contrast, little is known of response predictors in obsessive-compulsive disorder (OCD), a disorder with among the lowest proportion of responders to medication (40-60%). Our study is the largest investigation to date (N= 184) of treatment response and side effects to antidepressants in OCD based on metabolizer status for CYP2D6 and CYP2C19. We observed significantly more failed medication trials in CYP2D6 non-extensive compared with extensive metabolizers (P= 0.007). CYP2D6 metabolizer status was associated with side effects to venlafaxine (P= 0.022). There were nonsignificant trends for association of CYP2D6 metabolizer status with response to fluoxetine (P= 0.056) and of CYP2C19 metabolizer status with response to sertraline (P= 0.064). Our study is the first to indicate that CYP genes may have a role in antidepressant response in OCD. More research is required for a future clinical application of genetic testing, which could lead to improved treatment outcomes.
引用
收藏
页码：176 / 181
页数：6
相关论文
共 50 条
  • [21] CYP2D6 and CYP2C19 genotypes in an elderly Swedish population
    Yamada, H
    Dahl, ML
    Lannfelt, L
    Viitanen, M
    Winblad, B
    Sjöqvist, F
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (06) : 479 - 481
  • [22] The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype
    Ayman Al-Shurbaji
    Juliette Säwe
    European Journal of Clinical Pharmacology, 2002, 57 : 877 - 881
  • [23] Correction: Methodology for clinical genotyping of CYP2D6 and CYP2C19
    Beatriz Carvalho Henriques
    Avery Buchner
    Xiuying Hu
    Yabing Wang
    Vasyl Yavorskyy
    Keanna Wallace
    Rachael Dong
    Kristina Martens
    Michael S. Carr
    Bahareh Behroozi Asl
    Joshua Hague
    Sudhakar Sivapalan
    Wolfgang Maier
    Mojca Z. Dernovsek
    Neven Henigsberg
    Joanna Hauser
    Daniel Souery
    Annamaria Cattaneo
    Ole Mors
    Marcella Rietschel
    Gerald Pfeffer
    Stacey Hume
    Katherine J. Aitchison
    Translational Psychiatry, 12
  • [24] The pharmacokinetics of ketobemidone are not affected by CYP2D6 or CYP2C19 phenotype
    Al-Shurbaji, A
    Säwe, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 57 (12) : 877 - 881
  • [25] CYP2D6 and CYP2C19 genotypes in an elderly Swedish population
    H. Yamada
    M.-L. Dahl
    L. Lannfelt
    M. Viitanen
    B. Winblad
    F. Sjöqvist
    European Journal of Clinical Pharmacology, 1998, 54 : 479 - 481
  • [26] Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans
    Bottiger, Y
    Dostert, P
    Benedetti, MS
    Bani, M
    Fiorentini, F
    Casati, M
    Poggesti, I
    Alm, C
    Alvan, G
    Bertilsson, L
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 42 (06) : 707 - 711
  • [27] Efficient Methodology for Genotyping CYP2D6 and CYP2C19 for Neuropsychopharmacology
    Jiang, Shixie
    Huang, Jingyu
    Yang, Hao
    Wagoner, Ryan
    Currier, Glenn
    Kozel, Frank
    Jiang, Huabei
    NEUROPSYCHOPHARMACOLOGY, 2020, 45 (SUPPL 1) : 224 - 225
  • [28] DISTRIBUTION OF THE CYP2C19*2, CYP2C19*3 AND CYP2C19*4 GENE VARIANTS IN A ROMANIAN POPULATION
    Buzoianu, A. D.
    Trifa, A. P.
    Popp, R. A.
    Militaru, C. F.
    Bocsan, C., I
    Popp, I., V
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 80 - 80
  • [29] Forensic toxicology:: development of an SNP-assay for genotyping CYP2D6 and CYP2C19 variants
    Verrecas, M
    Knaepen, K
    Gifissen, A
    Cassiman, J
    Decorte, R
    PROGRESS IN FORENSIC GENETICS 10, 2004, 1261 : 583 - 585
  • [30] Allele frequencies of CYP2D6 and CYP2C19 variants in a hospital psychiatric population and their clinical relevance
    Boulamery, A.
    Berge-Lefranc, J. L.
    Saut, N.
    Richieri, R. M.
    Morange, P.
    Padovani, R.
    Enjalbert, A.
    Lancon, C.
    Bruguerolle, B.
    Simon, N.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2012, 26 : 81 - 81
12345